Cleveland Clinic Diabetes Therapeutics, Technology and Surgery
For over twenty five years, Cleveland Clinic has been at the forefront of diabetes treatment, research and education. Its world class faculty has designed Diabetes Therapeutics, Technology and Surgery to provide up-to-date reviews of management strategies and research on the complications of this disease. It includes a detailed analysis of therapeutic options applicable to type 1 and type 2 diabetes, as well as their complications.
Worth 6.25 AMA PRA Category I Credits™, this enduring material is designed for primary care physicians, endocrinologists, diabetes educators, nurses, nurse practitioners, physician assistants and dietitians, with NO POST TEST. Additionally, physicians can earn up to 6.25 ABIM MOC points for this activity.
6.25 AMA PRA Category I Credits™ Accredited for 6.25 ABIM MOC points. No Post Test!
Pump updates, dual hormone therapies, sulfonylureas, GLP1 agonists, metformin, and the role of exercise and fasting. The pathophysiologic impact of COVID-19 will also be explored.
Following this enduring material, the participants will be able to:
1. Describe the efficacy and side effects of therapeutic innovations for type 1 diabetes, including closed-loop insulin pumps, dual hormone therapy and glucagon.
2. Compare the effectiveness of new and emerging therapies for both type 1 and 2 diabetes.
3. Critically appraise the impact of bariatric surgery on patients with type 2 diabetes.
4. Describe options for treating children with type 2 diabetes.
5. Compare the data on effectiveness of diets and exercise in diabetes strategies.
6. Summarize research defining the pathophysiologic impact of nonalcoholic steatohepatitis.
7. Describe how COVID-19 affects the progression of diabetes in infected patients.
This activity is designed for primary care physicians, endocrinologists, diabetes educators, nurses, nurse practitioners, physician assistants, dietitians, and other health care professionals who care for patients with diabetes.
Additional credit info
Release Date: 7/1/21 CME Expiration 6/30/23